A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R.sub.3 are in vicinal position (if m=0 then R.sub.3 is in position 2′, and if m=1 then R.sup.3 is on position 1′); R is ethyl or vinyl; R.sub.1 is hydrogen or (C1-6)alkyl; R.sub.2 is hydrogen or—(C.sub.3-6)cycloalkyl, or—unsubstituted (C.sub.1-6)alkyl, or—(C.sub.1-6)alkyl substituted by one or more of—hydroxy; preferably one or two,—methoxy,—halogen,—(C.sub.3-6)cycloalkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e. g. selected from N or O, or R.sub.1 is hydroxy and R.sub.2 is formyl; R.sub.3 is OH, OR.sub.4, a halogen atom, or—with the proviso that R.sub.3 is bound to 2′ R.sub.3 represents —O—(CH.sub.2)P—O— with p is 2 or 3; R.sub.4 is unsubstituted (C.sub.1-6)alkyl or (C.sub.3-6)cycloalkyl.

A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R.sub.3 are in vicinal position (if m=0 then R.sub.3 is in position 2′, and if m=1 then R.sup.3 is on position 1′); R is ethyl or vinyl; R.sub.1 is hydrogen or (C1-6)alkyl; R.sub.2 is hydrogen or—(C.sub.3-6)cycloalkyl, or—unsubstituted (C.sub.1-6)alkyl, or—(C.sub.1-6)alkyl substituted by one or more of—hydroxy; preferably one or two,—methoxy,—halogen,—(C.sub.3-6)cycloalkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e. g. selected from N or O, or R.sub.1 is hydroxy and R.sub.2 is formyl; R.sub.3 is OH, OR.sub.4, a halogen atom, or—with the proviso that R.sub.3 is bound to 2′ R.sub.3 represents —O—(CH.sub.2)P—O— with p is 2 or 3; R.sub.4 is unsubstituted (C.sub.1-6)alkyl or (C.sub.3-6)cycloalkyl.

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.

The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.

The present invention relates to compounds of formula (I) as herein defined, capable of releasing fragrant compounds in a controlled manner into the surroundings. The present invention is also concerned with a process for their production, and consumer products comprising them.

The present invention relates to compounds of formula (I) as herein defined, capable of releasing fragrant compounds in a controlled manner into the surroundings. The present invention is also concerned with a process for their production, and consumer products comprising them.

A high-molecular-weight compound having a plurality of polymer chains linked through a divalent or higher-valent linking group, in which the divalent or higher-valent linking group has a thiol group and at least one of a thioether structure and a thiourethane structure, and a ratio of an absolute weight-average molecular weight to a relative weight-average molecular weight (absolute Mw/relative Mw) of the high-molecular-weight compound is 1.25 or more; and a method for producing the same are provided.

Described herein are compounds including at least one β-thio carbonyl or nitrile moiety capable of liberating an active molecule selected from an α,β-unsaturated ketone, aldehyde or nitrile. Also described herein are methods of using said compounds in perfumery as well as perfuming compositions or perfumed articles including the compounds. The compounds are represented by formula (I) where: a) m represents an integer from 1 to 6; b) Pro represents a hydrogen atom or a group susceptible of generating an odoriferous α,β-unsaturated ketone, aldehyde or nitrile and is represented by the formulae (II) or (II′) in which the wavy line indicates the location of the bond between said Pro and the sulfur atom S; and at least one of the Pro groups is of the formula (II) or (II′).

##STR00001##